<DOC>
	<DOCNO>NCT02531191</DOCNO>
	<brief_summary>The objective study evaluate bioequivalence new tablet versus current tablet ASP015K fasting condition single oral administration healthy male subject .</brief_summary>
	<brief_title>Bioequivalence Evaluation New Current Tablet ASP015K</brief_title>
	<detailed_description>This open-label , randomize , single dose , 2-way crossover design study . Forty non-elderly healthy male subject receive ASP015K small tablet ASP015K current tablet period fast condition . If bioequivalence two tablet demonstrate insufficient number , add-on subject study conduct need . The design add-on subject study initial study .</detailed_description>
	<criteria>50.0 kg ≤ body weight screen &lt; 80.0 kg 17.6 ≤ BMI screen &lt; 26.4 [ BMI = Body weight ( kg ) / ( Body height ( ) ) 2 ] Subjects agree use follow highly effective contraception consist two form birth control ( least one must barrier method ) start write informed consent 90 day study drug administration Period 2 . Subjects agree donate sperm start informed consent 90 day study drug administration Period 2 . Subjects judge healthy investigator subinvestigator base physical examination ( subjective symptom objective finding ) clinical test obtain screen checkin immediately study drug administration Period 1 . Subjects receive investigational drug within 120 day prior screen plan receive investigational drug screen assessment checkin Period 1 ( Day 1 ) . Any blood donation blood draw apply follow : Whole blood collection ( ≥ 400 mL ) : 90 day prior screen checkin Period 1 ( Day 1 ) Whole blood collection ( ≥ 200 mL ) : 30 day prior screen checkin Period 1 ( Day 1 ) Platelet plasma donation : 30 day prior screen checkin Period 1 ( Day 1 ) Subjects use plan use prescribe nonprescribed drug within 7 day prior checkin Period 1 ( Day 1 ) . Any deviation blood pressure , pulse , body temperature , 12lead ECG screen checkin Period 1 ( Day 1 ) follow normal range : Supine pressure : Systolic : ≥ 90 mmHg , ≤ 140 mmHg ; Diastolic : ≥ 40 mmHg , ≤ 90 mmHg Supine pulse : ≥ 40 bpm , ≤ 99 bpm Axillary temperature : ≥ 35.0 ºC , ≤ 37.0 ºC 12lead ECG : Normal clinically irrelevant abnormality QTc interval : ≥ 330 msec , &lt; 430 msec Any deviation laboratory test Screening Day 1 ( checkin ) Period 1 follow normal range . Normal range test test assay site use . Hematology : &gt; 20 % upper limit &lt; 20 % low limit . Chemistry : deviation ALT , AST , Cre , blood electrolyte ( Na , K , Cl ) , fast blood glucose . &gt; 20 % upper limit &lt; 20 % low limit test ; however low limit set respect ALT , AST , γGTP , TBil , ALP , LDH , CK , TCho , TG , Cre , UA . Urinalysis ( qualitative ) : deviation urinalysis . Urinary drug abuse test : positive benzodiazepine , cocainebased narcotic , analeptic drug , cannabis , barbituric acid derivative , morphinebased narcotic , phencyclidine , tricyclic antidepressant . Immunological test : positive HBs antigen , HBc antibody , HCV antibody , HIV antigen antibody , syphilis . Subjects history complication drug allergy . Subjects history upper gastrointestinal symptom , i.e . nausea , vomit , stomach ache , etc . within 7 day prior checkin Period 1 ( Day 1 ) . Subjects history complication hepatic disease , i.e . viral hepatitis , drug induce liver injury , hepatic dysfunction , etc . Subjects history complication cardiac disease , i.e . congestive heart failure , angina , arrhythmia require treatment , etc . Subjects history complication respiratory disease , i.e . bronchial asthma , chronic bronchitis , pneumonitis , etc . ( except history asthma childhood ) Subjects history complication gastrointestinal disease , i.e . peptic ulcer , reflux esophagitis , etc . ( except history appendicitis ) Subjects history gastrointestinal resection ( except history appendectomy ) Subjects history complication renal disease , i.e . acute renal failure , glomerulonephritis , intestinal nephritis , etc . Subjects history complication endocrine disease , i.e . hyperthyroidism , abnormality growth hormone , etc . Subjects history complication cerebrovascular disorder , i.e . cerebral infarction . Subjects history complication malignant tumor . Subjects history complication congenital short QT syndrome . Subjects history complication lymphatic disease , i.e . lymphoproliferative disease . Subjects follow apply regard tuberculosis : History active tuberculosis Abnormality chest Xray test screen Contact patient infectious tuberculosis Subjects follow apply regard infectious disease tuberculosis : History complication serious herpes zoster disseminate herpes zoster More relapse localized herpes zoster Hospitalization due serious infection within 90 day checkin Period 1 ( Day 1 ) I.V . antibiotic treatment within 90 day checkin Period 1 ( Day 1 ) ( except prevention use ) Judged prone infection investigator subinvestigator , i.e . subject urethral catheterization . Subjects history inoculation live vaccine attenuate live vaccine within 56 day prior checkin Period 1 ( Day 1 ) . Subjects history clinically serious allergy ( Clinically serious allergy ; allergy induced systemic urticaria anaphylactic shock require hospitalization expose specific antigen drug ) . Subjects history complication heart failure classify NYHA Class III IV . Subjects history ASP015K administration . Subjects excessive alcohol drinking smoking . Criteria `` excessive '' : 1 . Smoking : ≥ 20 cigarettes/day 2 . Alcohol drinking : ≥ 45 g/day ( large bottle beer contain 25 g alcohol , 1 gou Japanese sake contain 22 g alcohol ) Employee sponsor , CROs study site involve study . Subjects judge inappropriate study investigator subinvestigators .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>JAK inhibitor</keyword>
	<keyword>bioequivalence study</keyword>
</DOC>